Reconciliation limitations led CMS to overpay hospitals $500M

Hospitals were overpaid by roughly $502 million from 2011 to 2014, according to a report from the Office of Inspector General (OIG), which blamed the overpayment on CMS limitations on the reconciliation period.

Sixty hospitals were paid $502 million more in net outlier payments than they were owed, the report found. Of those hospitals, 53 were overpaid by $541 million, while seven were underpaid $39 million. Across the four-year period, 34 hospitals received outlier payments every year. Over all four years, CMS made more than $18 billion in outlier payments to 3,366 hospitals.

According to OIG, the payment errors were not found by CMS because they didn’t meet the reconciliation requirements of a 10% threshold of cost reports. Hospitals charged higher prices than the rate of cost increases below the 10% threshold, which meant their cost-to-charge ratio (CCR) didn’t trigger reconciliation. CMS set this threshold because the agency believed it would capture the outlier payments that were substantially inaccurate.

However, lower percentage cost changes were not found. For example, 216 of 236 cost reports reconciled by OIG had a change of less than 5 percentage points in their CCRs.

The findings prompted OIG to suggest CMS requires reconciliation of all hospital cost reports with outlier payments in a cost-reporting period. For the 7 reporting Medicare Administrative Contractors (MACs) to reconcile all the 236 cost reports measured by OIG, the cost would range from $47,200 to $1.7 million for the four-year period, OIG estimated. The annual savings for reconciling all cost reports with outlier payments would reach approximately $125 million.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.